'Unprecedented' biotech bankruptcies erupt amid finance crisis Nov 30, 2008
-based Genelabs Technologies Inc., a developer of hepatitis C treatments, which agreed on Oct. 29 to be bought by GlaxoSmithKline Plc, Europe's biggest drugmaker, for $57 million. Genelabs' market value had plunged to $10 million and its stock had lost 82 percent of its value this year before the deal was announced. (The Palm Beach Post)
U.S. biotech IPOs dying on the vine Nov 1, 2008
This week, GlaxoSmithKline purchased Genelabs Technologies, which develops therapies against hepatitis C, for $57 million. Swiss drugmaker Roche Holding is trying to buy the shares in Genentech it does not already own for $43. (USA Today -- Tech)
Glaxo Saves Genelabs Oct 31, 2008
30 per share, for Genelabs Technologies (nasdaq: - - ), a small therapeutics company that specializes in hepatitis C drugs in early stages of development. GlaxoSmithKline (nyse: - - ) will be able to tack this company's technology platform and its early-stage drugs onto its already dominant HIV treatment unit. (Forbes -- Markets)
Glaxo to buy hepatitis C-vaccine company Oct 31, 2008
GlaxoSmithKline to buy Genelabs Technologies for $57M - Triangle Business Journal ... GlaxoSmithKline to buy Genelabs Technologies for $57M. (Raleigh Triangle Business Journal, NC)
GlaxoSmithKline to Acquire Genelabs Technologies to Increase Focus on Novel Small Molecule Therapies for Hepatitis C Oct 30, 2008
PHILADELPHIA, Oct. 29 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) (LSE: GSK) and Genelabs Technologies, Inc. (Nasdaq: ) announced today that they have entered into a definitive agreement pursuant to which GSK will acquire Genelabs for approximately $57 million (pounds Sterling 35 million) through a tender offer of $1 ... About Genelabs Technologies Genelabs is a biopharmaceutical company focused on the discovery and development of novel compounds for infectious diseases. (PR Newswire)
Genelabs Technologies makes Driscoll sole CEO Sep 4, 2008
Genelabs Technologies makes Driscoll sole CEO - Silicon Valley / San Jose Business Journal ... Genelabs Technologies makes Driscoll sole CEO. (San Jose Business Journal, CA)
Matthew J. Pfeffer Joins MannKind as Corporate Vice President and Chief Financial Officer Apr 17, 2008
Mr. Pfeffer is a member of the board of directors of Genelabs Technologies, Inc. He also serves on boards and advisory committees of Financial Executives International, the Biotechnology Industry Organization and the American Institute of Certified Public Accountants. Mr. Pfeffer graduated from the University of California, Berkeley and is a Certified Public Accountant. (PR Newswire)
Genelabs Technologies, Inc. Announces Resignation of President and CEO Jan 31, 2008
Jan. 30 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (Nasdaq: ) announced today that James A. D. Smith has resigned as President, Chief Executive Officer and Director of the company, effective January 29, 2008 ... About Genelabs Technologies Genelabs Technologies, Inc. is a biopharmaceutical company focused on the discovery and development of pharmaceutical products to improve human health ... Note: Genelabs(R) and the Genelabs logo are registered trademarks of Genelabs Technologies,... (PR Newswire)
viral hepatitis Jul 23, 2007
But meanwhile, independently, a group working for Genelabs Technologies identified a virus in the plasma of a patient with chronic hepatitis and named it HGV. It is now recognised that GBV-C and HGV are independent isolates of the same virus. Is hepatitis H virus waiting in the wings. (Suite101.com)
Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at 20th International Conference on Antiviral Research Meeting May 3, 2007
May 2 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. (Nasdaq: ) announced today that a presentation was made today at the 20th International Conference on Antiviral Research being held in Palm Springs, California, on a non-nucleoside hepatitis C virus (HCV) polymerase inhibitor discovered by Genelabs ... "Furthermore, we believe future treatment of HCV is likely to involve combinations of antiviral drugs and these data suggest that combinations of this type of non-nucleoside agent with... (PR Newswire)
